The new guidelines offer guidance on dosing, including reduced starting and maintenance dosing and safety precautions for diagnosing and treating complications.
Clinically and statistically significant reductions in peripheral neuropathy were seen following neurofeedback.
Spinal cord stimulation using precision approach via 3D neural targeting shows superior efficacy in treating chronic axial low back pain compared with a trial-and-error method to achieve desired paresthesia.
The recommendations promote the use of hot compresses and physical therapy as first-line treatment of low back pain.
New research suggests that opioid addiction may be linked to a genetic variant, and more personalized treatment may help those with the change.
Interventions with clinical massage or guided imagery may help ease pain and anxiety in patients in a progressive care unit.
The abuse of opioids or other substances may cause short-term amnesia.
Patients with successful spinal cord stimulation implants had significantly reduced opioid use 1 year post-implant.
Effectively treating pain may help improve cognitive and functional outcomes in patients with depression.
The FDA instituted widespread updates to product labeling for opioid medications in December, 2016.
Rates of severe pain were significantly higher in veterans with back and jaw pain, severe headaches or migraine, and neck pain.
Neurology Advisor Articles
- Self-Controlled Electric Stimulation a Good Alternative to Drug Therapy for Migraine
- Elevated Copeptin Levels in Acute Headache May Signify More Serious Etiology
- New Sleep Apnea Clinical Practice Guidelines
- Patent Foramen Ovale Closure Reduces Stroke Risk in Patients With Inherited Thrombophilias
- Neural Targeting Spinal Cord Stimulation Superior for Axial Low Back Pain
- DHA Supplementation Has No Impact on IQ in Offspring
- Safinamide Approved as Adjunctive Therapy for Parkinson's
- International League Against Epilepsy Updates Epilepsy Classification System
- Depression, Schizophrenia Identified With Objective Blood Biomarker
- Autoimmune Disease Hospitalization Linked to Future Dementia Risk